{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:25:56Z","timestamp":1789928756375,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,7,30]],"date-time":"2013-07-30T00:00:00Z","timestamp":1375142400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Altern Med"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Rhabdomyolysis is an uncommon side effect of trabectedin which is used for the second line therapy of metastatic sarcoma after anthracycline and ifosfamide failure. This side effect may be due to pharmacokinetic interactions caused by shared mechanisms of metabolism involving the cytochrome P450 (CYP) system in the liver. Here, for the first time in literature, we describe the unexpected onset of heavy toxicity, including rhabdomyolysis, after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>This is the case of a 56 year old Caucasian man affected by a relapsed de-differentiated liposarcoma who, after the fourth cycle of second-line chemotherapy with trabectedin, complained of sudden weakness, difficulty walking and diffuse muscle pain necessitating complete bed rest. Upon admission to our ward the patient showed grade (G) 4 pancytopenia and a marked increase in liver lytic enzymes, serum levels of myoglobin, creatine phosphokinase (CPK) and lactate dehydrogenase. No cardiac or kidney function injuries were present. Based on these clinical and laboratory features, our conclusive diagnosis was of rhabdomyolysis induced by trabectedin.<\/jats:p>\n            <jats:p>The patient did not report any trauma or muscular overexertion and no co-morbidities were present. He had not received any drugs during treatment with trabectedin, but upon further questioning the patient informed us he had been taking a folk medicine preparation of chokeberry (<jats:italic>Aronia melanocarpa<\/jats:italic>) daily during the last course of trabectedin and in the 2 subsequent weeks.<\/jats:p>\n            <jats:p>One week after hospitalization and cessation of intake of chokeberry extract, CPK and other markers of myolysis slowly returned to standard range, and the patient noted a progressive recovery of muscle strength.<\/jats:p>\n            <jats:p>The patient was discharged on day 14 when a blood transfusion and parenteral hydration gradually lowered general toxicity. Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The level of evidence of drug interaction leading to the adverse event observed in our patient was 2 (probable). Thus our case underlines the importance of understanding rare treatment-related toxicities such as trabectedin-induced rhabdomyolysis and the possible role of the drug-drug interactions in the pathogenesis of this rare side effect. Furthermore, this report draws attention to a potential problem of particular concern, that of nutritional supplements and complementary and alternative drug interactions. These are not widely recognized and can cause treatment failure.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1472-6882-13-199","type":"journal-article","created":{"date-parts":[[2013,7,30]],"date-time":"2013-07-30T16:14:20Z","timestamp":1375200860000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin"],"prefix":"10.1186","volume":"13","author":[{"given":"Sabino","family":"Strippoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,30]]},"reference":[{"issue":"7","key":"1449_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1056\/NEJMra041866","volume":"353","author":"MA Clark","year":"2005","unstructured":"Clark MA, Fisher C, Judson I, Thomas JM: Soft-tissue sarcomas in adults. N Engl J Med. 2005, 353 (7): 701-711. 10.1056\/NEJMra041866.","journal-title":"N Engl J Med"},{"issue":"25","key":"1449_CR2","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, G\u00f3mez J, Park YC, Le Cesne A: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009, 27 (25): 4188-4196. 10.1200\/JCO.2008.21.0088.","journal-title":"J Clin Oncol"},{"key":"1449_CR3","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00280-012-1864-4","volume":"69","author":"F Grosso","year":"2012","unstructured":"Grosso F, D\u2019Incalci M, Cartoafa M, Nieto A, Fernandez-Teruel C, Alfaro V, Lardelli P, Roy E, Gomez J, Kahatt C, Soto-Matos A, Judson I: A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin. Cancer Chemother Pharmacol. 2012, 69: 1557-1565. 10.1007\/s00280-012-1864-4.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"1449_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/PAP.0b013e3181bb6b86","volume":"16","author":"MR Tanas","year":"2009","unstructured":"Tanas MR, Goldblum JR: Fluorescence in situ hybridization in the diagnosis of soft tissue neoplasms: a review. Adv Anat Pathol. 2009, 16 (6): 383-391. 10.1097\/PAP.0b013e3181bb6b86.","journal-title":"Adv Anat Pathol"},{"key":"1449_CR5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/030089161109700223","volume":"97","author":"A Stoyianni","year":"2011","unstructured":"Stoyianni A, Kapodistrias N, Kampletsas E, Pentheroudakis G, Pavlidis N: Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity. Tumori. 2011, 97: 252-255.","journal-title":"Tumori"},{"key":"1449_CR6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/030089161109700224","volume":"97","author":"F Grosso","year":"2011","unstructured":"Grosso F, D\u2019Incalci M: Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin. Tumori. 2011, 97: 256-257.","journal-title":"Tumori"},{"key":"1449_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10637-005-4538-9","volume":"24","author":"EF Brandon","year":"2006","unstructured":"Brandon EF, Sparidans RW, Guijt KJ, Lowenthal S, Meijerman I, Beijnen JH, Schellens JH: In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectedin), a novel marine anti-cancer drug. Invest New Drugs. 2006, 24: 3-14. 10.1007\/s10637-005-4538-9.","journal-title":"Invest New Drugs"},{"key":"1449_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/jnci\/djk130","volume":"99","author":"RP Riechelmann","year":"2007","unstructured":"Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK: Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007, 99: 592-600. 10.1093\/jnci\/djk130.","journal-title":"J Natl Cancer Inst"},{"key":"1449_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00520-006-0168-9","volume":"15","author":"S Milazzo","year":"2007","unstructured":"Milazzo S, Lejeune S, Ernst E: Laetrile for cancer: a systematic review of the clinical evidence. Support Care Cancer. 2007, 15: 583-595. 10.1007\/s00520-006-0168-9.","journal-title":"Support Care Cancer"},{"key":"1449_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/1534735408330202","volume":"8","author":"S Engdal","year":"2009","unstructured":"Engdal S, Klepp MO, Nilsen OG: Identification and exploration of herb-drug combinations used by cancer patients. Integr Cancer Ther. 2009, 8: 29-36. 10.1177\/1534735408330202.","journal-title":"Integr Cancer Ther"},{"issue":"2","key":"1449_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2165\/11597910-000000000-00000","volume":"51","author":"S Shi","year":"2012","unstructured":"Shi S, Klotz U: Drug interactions with herbal medicines. Clin Pharmacokinet. 2012, 51 (2): 77-104. 10.2165\/11597910-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1449_CR12","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.fct.2006.04.008","volume":"44","author":"CY Yang","year":"2006","unstructured":"Yang CY, Chao PD, Hou YC, Tsai SY, Wen KC, Hsiu SL: Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats. Food Chem Toxicol. 2006, 44 (9): 1572-1578. 10.1016\/j.fct.2006.04.008.","journal-title":"Food Chem Toxicol"},{"issue":"2","key":"1449_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/ptr.2572","volume":"23","author":"JC Tang","year":"2009","unstructured":"Tang JC, Yang H, Song XY, Song XH, Yan SL, Shao JQ, Zhang TL, Zhang JN: Inhibition of cytochrome P450 enzymes by rhein in rat liver microsomes. Phytother Res. 2009, 23 (2): 159-164. 10.1002\/ptr.2572.","journal-title":"Phytother Res"},{"issue":"12","key":"1449_CR14","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1158\/1055-9965.EPI-06-0365","volume":"15","author":"HH Chow","year":"2006","unstructured":"Chow HH, Hakim IA, Vining DR, Crowell JA, Cordova CA, Chew WM, Xu MJ, Hsu CH, Ranger-Moore J, Alberts DS: Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev. 2006, 15 (12): 2473-2476. 10.1158\/1055-9965.EPI-06-0365.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"1449_CR15","first-page":"88","volume":"294","author":"RS Obach","year":"2000","unstructured":"Obach RS: Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther. 2000, 294 (1): 88-95.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"1449_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1177\/0091270003253636","volume":"43","author":"GD Anderson","year":"2003","unstructured":"Anderson GD, Rosito G, Mohustsy MA, Elmer GW: Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol. 2003, 43 (6): 643-648.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1449_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1742-7843.2008.00307.x","volume":"103","author":"TS Hansen","year":"2008","unstructured":"Hansen TS, Nilsen OG: In vitro CYP3A4 metabolism: inhibition by Echinacea purpurea and choice of substrate for the evaluation of herbal inhibition. Basic Clin Pharmacol Toxicol. 2008, 103 (5): 445-449. 10.1111\/j.1742-7843.2008.00307.x.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1449_CR18","doi-asserted-by":"crossref","first-page":"806S","DOI":"10.1093\/jn\/136.3.806S","volume":"136","author":"DJ Greenblatt","year":"2006","unstructured":"Greenblatt DJ, Leigh-Pemberton RA, von Moltke LL: In vitro interactions of water-soluble garlic components with human cytochromes p450. J Nutr. 2006, 136: 806S-809S.","journal-title":"J Nutr"},{"key":"1449_CR19","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1055\/s-0028-1088306","volume":"74","author":"SE Kulling","year":"2008","unstructured":"Kulling SE, Rawel HM: Chokeberry (Aronia melanocarpa) \u2013 a review on the characteristic components and potential health effects. Planta Med. 2008, 74: 1625-1634. 10.1055\/s-0028-1088306.","journal-title":"Planta Med"},{"issue":"4","key":"1449_CR20","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12272-011-0411-x","volume":"34","author":"JS Choi","year":"2011","unstructured":"Choi JS, Piao YJ, Kang KW: Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res. 2011, 34 (4): 607-613. 10.1007\/s12272-011-0411-x.","journal-title":"Arch Pharm Res"},{"key":"1449_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1207\/s15327914nc5401_10","volume":"54","author":"G Lala","year":"2006","unstructured":"Lala G, Malik M, Zhao CW, He J, Kwon Y, Giusti MM: Anthocyaninrich extracts inhibit multiple biomarkers of colon cancer in rats. Nutr Cancer. 2006, 54: 84-93. 10.1207\/s15327914nc5401_10.","journal-title":"Nutr Cancer"},{"issue":"1","key":"1449_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/09537100701708506","volume":"19","author":"B Olas","year":"2008","unstructured":"Olas B, Wachowicz B, Tomczak A, Erler J, Stochmal A, Oleszek W: Comparative anti-platelet and antioxidant properties of polyphenol-rich extracts from: berries of Aronia melanocarpa, seeds of grape and bark of Yucca schidigera in vitro. Platelets. 2008, 19 (1): 70-77. 10.1080\/09537100701708506.","journal-title":"Platelets"},{"issue":"2","key":"1449_CR23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.etap.2010.12.006","volume":"31","author":"H Szaefer","year":"2011","unstructured":"Szaefer H, Krajka-Ku\u017aniak V, Ignatowicz E, Adamska T, Baer-Dubowska W: Chokeberry (Aronia melanocarpa) juice modulates 7,12-dimethylbenz[a]anthracene induced hepatic but not mammary gland phase I and II enzymes in female rats. Environ Toxicol Pharmacol. 2011, 31 (2): 339-346. 10.1016\/j.etap.2010.12.006.","journal-title":"Environ Toxicol Pharmacol"},{"key":"1449_CR24","volume-title":"Drug interaction facts","author":"DS Tatro","year":"2009","unstructured":"Tatro DS: Drug interaction facts. 2009, St. Louis: Facts and Comparisons"},{"key":"1449_CR25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1159\/000323261","volume":"3","author":"W Lamm","year":"2010","unstructured":"Lamm W, Amann G, Brodowicz T: Case report of suspected Rhabdomyolysis during treatment with Trabectedin in a patient with Metastatic Leiomyosarcoma. Case Rep Oncol. 2010, 3: 477-479. 10.1159\/000323261.","journal-title":"Case Rep Oncol"},{"key":"1449_CR26","first-page":"1011","volume":"10","author":"KY Yap","year":"2009","unstructured":"Yap KY, Kuo EY, Lee JJ, Chui WK, Chan A: An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project. Support Care Cancer. 2009, 10: 1011-1019.","journal-title":"Support Care Cancer"}],"container-title":["BMC Complementary and Alternative Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6882-13-199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6882-13-199\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6882-13-199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6882-13-199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:50:07Z","timestamp":1630543807000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/1472-6882-13-199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,30]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1449"],"URL":"https:\/\/doi.org\/10.1186\/1472-6882-13-199","relation":{},"ISSN":["1472-6882"],"issn-type":[{"value":"1472-6882","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,30]]},"assertion":[{"value":"7 January 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"199"}}